NCT05904496 - A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 19, 2023

Primary Completion Date

August 20, 2025

Study Completion Date

August 20, 2025

Conditions

Advanced Solid Tumors

Interventions

DRUG

BGB-30813

Specified dose administered on specified days

DRUG

Tislelizumab

Specified dose administered on specified days

Trial Locations (11)

Peter Maccallum Cancer Centre, Melbourne

Monash Health, Clayton

Linear Clinical Research, Nedlands

Start Madrid Fundacion Jimenez Diaz, Madrid

Jinan Central Hospital, Jinan

Shandong Provincial Hospital, Jinan

Shandong Cancer Hospital, Jinan

Hackensack University Medical Center, Hackensack

Md Anderson Cancer Center, Houston

Next Oncology, San Antonio

Hospital Universitario Vall Dhebron, Barcelona